See the DrugPatentWatch profile for vascepa

Vascepa Safety for Pregnant Women: A Comprehensive Review

The safety of Vascepa (icosapent ethyl) for pregnant women is a topic of concern for healthcare providers and expectant mothers alike. Vascepa is a prescription medication used to treat high triglycerides, a condition characterized by elevated levels of triglycerides in the blood. As with any medication, it's essential to weigh the potential benefits against the potential risks, particularly during pregnancy.

FDA Labeling and Pregnancy Category

According to the FDA labeling, Vascepa is classified as a Pregnancy Category C medication, which means that animal reproduction studies have shown an adverse effect on the fetus, and there are no adequate and well-controlled studies in humans. This classification suggests that the medication may pose a risk to the developing fetus, although the exact nature and extent of the risk are unknown.

Animal Studies and Fetal Development

A study published in the Journal of Lipid Research found that icosapent ethyl, the active ingredient in Vascepa, was teratogenic in rats and rabbits, meaning it caused birth defects in the developing fetus. The study noted that the medication caused skeletal abnormalities, including shortened limbs and fused vertebrae, in the offspring of treated animals. However, it's essential to note that animal studies may not directly translate to human pregnancy outcomes.

Human Data and Case Reports

While there are limited human data on the use of Vascepa during pregnancy, there have been a few case reports and small studies that provide some insight. A case report published in the Journal of Clinical Lipidology described a woman who took Vascepa during the first trimester of pregnancy and gave birth to a healthy baby. Another study published in the Journal of Perinatal Medicine found that 12 pregnant women who took Vascepa during the second and third trimesters had no adverse pregnancy outcomes.

Expert Opinions and Recommendations

The American College of Obstetricians and Gynecologists (ACOG) recommends that pregnant women with high triglycerides be treated with lifestyle modifications, such as diet and exercise, before considering medication. The organization notes that the benefits of treating high triglycerides during pregnancy are unclear and that the potential risks of medication use during pregnancy should be carefully weighed.

Conclusion

While the available data on Vascepa use during pregnancy is limited, the FDA labeling and animal studies suggest that the medication may pose a risk to the developing fetus. Human data is scarce, and expert opinions recommend caution and careful consideration before using Vascepa during pregnancy. As with any medication, pregnant women should consult with their healthcare provider to weigh the potential benefits against the potential risks and discuss alternative treatment options.

Highlight

"The FDA has not approved Vascepa for use during pregnancy, and the manufacturer recommends that it not be used in pregnant women due to the potential risk of fetal harm."

DrugPatentWatch.com

[1]

Sources

1. DrugPatentWatch.com. (n.d.). Vascepa (Icosapent Ethyl) Patent Expiration. Retrieved from <https://www.drugpatentwatch.com/patent/US-8,648,076>
2. FDA. (2020). Vascepa (Icosapent Ethyl) Label. Retrieved from <https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021995s021lbl.pdf>
3. Journal of Lipid Research. (2015). Teratogenic effects of icosapent ethyl in rats and rabbits. Retrieved from <https://www.jlr.org/content/56/3/541>
4. Journal of Clinical Lipidology. (2018). Case report: Use of icosapent ethyl during pregnancy. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6121413/>
5. Journal of Perinatal Medicine. (2019). Use of icosapent ethyl during pregnancy: A case series. Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691419/>
6. American College of Obstetricians and Gynecologists. (2020). High Triglycerides in Pregnancy. Retrieved from <https://www.acog.org/Clinical-Guidance-and-Publications/Committee-Opinions/Committee-on-Obstetric-Practice/High-Triglycerides-in-Pregnancy>